- Home
- FDMT vs KOD Comparison
FDMT vs KOD Comparison
Compare FDMT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- KOD
- Stock Information
- Founded
- FDMT 2013
- KOD 2009
- Country
- FDMT United States
- KOD United States
- Employees
- FDMT N/A
- KOD N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FDMT Health Care
- KOD Health Care
- Exchange
- FDMT Nasdaq
- KOD Nasdaq
- Market Cap
- FDMT 192.2M
- KOD 198.4M
- IPO Year
- FDMT 2020
- KOD 2018
- Fundamental
- Price
- FDMT $6.61
- KOD $8.55
- Analyst Decision
- FDMT Buy
- KOD Hold
- Analyst Count
- FDMT 9
- KOD 4
- Target Price
- FDMT $30.63
- KOD $11.75
- AVG Volume (30 Days)
- FDMT 733.0K
- KOD 647.2K
- Earning Date
- FDMT 08-11-2025
- KOD 08-13-2025
- Dividend Yield
- FDMT N/A
- KOD N/A
- EPS Growth
- FDMT N/A
- KOD N/A
- EPS
- FDMT N/A
- KOD N/A
- Revenue
- FDMT $33,000.00
- KOD N/A
- Revenue This Year
- FDMT $9,921.62
- KOD N/A
- Revenue Next Year
- FDMT N/A
- KOD N/A
- P/E Ratio
- FDMT N/A
- KOD N/A
- Revenue Growth
- FDMT N/A
- KOD N/A
- 52 Week Low
- FDMT $2.24
- KOD $1.92
- 52 Week High
- FDMT $17.41
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- FDMT 57.82
- KOD 50.31
- Support Level
- FDMT $5.97
- KOD $8.29
- Resistance Level
- FDMT $7.33
- KOD $9.23
- Average True Range (ATR)
- FDMT 0.48
- KOD 0.93
- MACD
- FDMT -0.11
- KOD -0.29
- Stochastic Oscillator
- FDMT 39.51
- KOD 8.64
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.